Rate dispute between John Hopkins All Children’s, UnitedHealth ‘causing angst’

A stalemate over reimbursement rates at John Hopkins All Children’s Hospital in St. Petersburg, Florida is causing some anxiety for patients and their families.

The Tampa Bay Times reported on one such family, the Shreeves, whose 5-year old son Gavin has a “rare autoinflammatory disease.” The family said they recently received two dozen letters from their insurer, UnitedHealthcare, telling them their physicians, therapists and lab technicians at All Children’s would no longer be in-network.

“It took us two years to put together our team of doctors,” Christina Shreeve said. “It runs like a well-oiled machine. I'm not going to get the same quality of care anywhere else.”

UnitedHealth is locked in an ongoing dispute over rates with All Children’s. The hospital asked for 60 percent increase in reimbursements, later lowering it to 35 percent, but UnitedHealth would only offer 20 percent. The contract expired May 11, and state law will allow patients receiving care to continue paying in-network rates for up to six months. In the Shreeve's case, however, UnitedHealth is only offering an extension through July 1, and the two sides don’t sound close to settling their differences.

"If they paid us anywhere near market (rate), I'd take it," said All Children’s President Jonathan Ellen, MD. "They just aren't negotiating in good faith."

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.